In vitro and in vivo growth inhibition of drug-resistant ovarian carcinoma cells using a combination of cisplatin and a TRAIL-encoding retrovirus

Oncology Letters

Volumn 4, Issue 6, 2012, Pages 1254-1258

  Li, Fang ^a,b   Guo, Yi ^a   Han, Lingfei ^a   Duan, Yankang ^a   Fang, Fang ^a   Niu, Sumei ^a   Ba, Qiujie ^a   Zhu, Huaishi ^c   Kong, Fanfei ^a   Lin, Chao ^b   Wen, Xuejun ^b  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b TONGJI UNIVERSITY   (China)

^c Huangpu District Central Hospital   (China)

Author keywords

Chemotherapy; Full length TRAIL; Gene therapy; Ovarian cancer; Retrovirus

Indexed keywords

CISPLATIN; ONCOLYTIC ADENOVIRUS; RETROVIRUS VECTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL A2780 DDP; CANCER CELL BOSC 23; CANCER GENE THERAPY; CANCER INHIBITION; CANCER RESISTANCE; CARCINOMA CELL; CELL LINE; GENETIC TRANSFECTION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY CARCINOMA; PROTEIN EXPRESSION; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING;

EID: 84867253999     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.926     Document Type: Article

References (22)

1. Landis SH, Murray T, Bolden S and Wingo PA: Cancer statistics, 1999. CA Cancer J Clin 49: 8-31, 1999.
2. Kaufmann SH and Earnshaw WC: Induction of apoptosis by cancer chemotherapy. Exp Cell Res 256: 42-49, 2001.
3. Fisher DE: Apoptosis in cancer therapy: crossing the threshold. Cell 78: 539-542, 1994.
4. Schmitt CA and Lowe SW: Apoptosis is critical for drug response in vivo. Drug Resist Updat 4: 132-134, 2001.
5. Baselga J, Norton L, Albanell J, Kim YM and Mendelsohn J: Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58: 2825-2831, 1998.
6. Cuello M, Ettenberg SA, Nau MM and Lipkowitz S: Synergistic induction of apoptosis by the combination of TRAIL and chemotherapy in chemoresistant ovarian cancer cells. Gynecol Oncol 81: 380-390, 2001.
7. Ferreira CG, Epping M, Kruyt FA and Giaccone G: Apoptosis: target of cancer therapy. Clin Cancer Res 8: 2024-2034, 2002.
8. Sheridan JP, Marsters SA, Pitti RM, et al: Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277: 818-821, 1997.
9. Ashkenazi A: Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2: 420-430, 2002.
10. Walczak H, Miller RE, Ariail K, et al: Tumoricidal activity of tumor necrosis factor related apoptosis-inducing ligand in vivo. Nat Med 5: 157-163, 1999.
11. Grotzer MA, Eggert A, Zuzak TJ, et al: Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression. Oncogene 19: 4604-4610, 2000.
12. Ma H, Liu Y, Liu S, Kung HF, Sun X, Zheng D and Xu R: Recombinant adeno-associated virus-mediated TRAIL gene therapy suppresses liver metastatic tumor. Int J Cancer 2: 314-321, 2005.
13. Griffith TS, Anderson RD, Davidson BL, Williams RD and Ratliff TL: Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/apo-2 ligand gene induces tumor cell apoptosis. J Immunol 165: 2886-2894, 2000.
14. Seol JY, Park KH, Hwang CI, et al: Adenovirus-TRAIL can overcome TRAIL resistance and induce a bystander effect. Cancer Gene Ther 10: 540-548, 2003.
15. Pan Q, Liu B, Liu J, Cai R, Wang Y and Qian C: Synergistic induction of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying TRAIL. Mol Cell Biochem 304: 315-323, 2007.
16. Keane MM, Ettenberg SA, Nau MM, Russell EK and Lipkowitz S: Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 59: 734-741, 1999.
17. Nagane M, Pan G, Weddle JJ, Dixit VM, Cavenee WK and Huang HJ: Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res 60: 847-853, 2000.
18. Krosl J, Baban S, Krosl G, Rozenfeld S, Largman C and Sauvageau G: Cellular proliferation and transformation induced by HOXB4 and HOXB3 proteins involves cooperation with PBX1. Oncogene 16: 3403-3412, 1998.
19. Jiang QL, Wang JM, Jiang S, Wen LM and Zhou H: Large-scale real-time titration of green-fluorescence-protein-marked recombinant retrovirus: comparison with standard titration method. Di Yi Jun Yi Da Xue Xue Bao 23: 1101-1103, 2003 (In Chinese).
20. Pear WS, Nolan GP, Scott ML and Baltimore D: Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 90: 8392-8396, 1993.
21. Kassis R, Larrous F, Estaquier J and Bourhy H: Lyssavirus matrix protein induces apoptosis by a TRAIL-dependent mechanism involving caspase-8 activation. J Virol 78: 6543-6555, 2004.
22. Seol DW, Li J, Seol MH, Park SY, Talanian RV and Billiar TR: Signaling events triggered by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): caspase-8 is required for TRAIL-induced apoptosis. Cancer Res 61: 1138-1143, 2001.